ArticleOncotarget2017

Pre-clinical pharmacology of AZD3965, a selective inhibitor of MCT1: DLBCL, NHL and Burkitt's lymphoma anti-tumor activity.

Nicola J Curtis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.